News & Media 26th Nov 2023

Quality Quagmire. Why drugmakers are dialing C for current good manufacturing practices

Authors

Ashishchandra Rao Partner | Mumbai

Latest Thought Leadership

News & Media 25th Jun 2024

Misleading Ads: Ambiguous Self-Declaration Rules Leave Advertisers in Compliance Limbo

Read More
News & Media 25th Jun 2024

Budget 2024 expectations: Will the government increase Section 80C limit

Read More
News & Media 25th Jun 2024

MC Exclusive: FSSAI calls for strict compliance of food safety protocols after alarming contamination reports

Read More
News & Media 25th Jun 2024

Budget 2024: AIFs seek tax parity with FPIs

Read More

Recently, two Indian companies have come in for observations from the US Food and Drug Administration (FDA) on their non-adherence to current Good Manufacturing Practices(cGMP). Concerns over cGMP is not something that’s surfacing today, nor is it restricted to Indian companies. But it is in the interest of Indian drugmakers to be up to scratch, given their role as a global supplier of medicines and as they step up into making more specialized medicines.

Against this background, Ashishchandra Rao, Partner, Economic Laws Practice (ELP) talks to Jyothi Datta from The Hindu businessline in the latest article “Quality Quagmire. Why drugmakers are dialing C for current good manufacturing practices” about the guidelines surrounding Good Manufacturing Practices(cGMP).

To know more, explore the article here